No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 15 of the 40 quarters in the window, leaving 25 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.3x · 10Y median 217.7x · 5th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:28:26.427Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T16:28:26.427Z. Latest historical point 2026-02-17.
The latest delayed quote for Palatin Technologies, Inc. (PTN) stock was $9.42 as of Oct 6, 2026, 12:17 PM EDT, down 0.63% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +20.7% · 3-year avg -52.9%/yr · 5-year avg -55.4%/yr
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.
Biotechnology · Monmouth Junction, NJ
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 16, 2026
41 days away
EPS Estimate
-0.42
Revenue Est.
$2.51M
Last Quarter Results
EPS
$-1.11
vs Estimate
$-1.20
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PTN | $16.76M | $9.42 | -0.63% | +20.66% | -55.41% | -35.08% | N/A |
| 2BNGO | $16.75M | $1.46 | +1.04% | -24.38% | -78.37% | N/A | vs PTN |
| 3PAVM | $16.98M | $2.66 | N/A | -79.49% | -76.55% | -54.03% | vs PTN |
| 4MRKR | $17.01M | $1.02 | -3.76% | +11.06% | -42.13% | -33.25% | vs PTN |
| 5DYAI | $16.48M | $0.45 | -0.35% | -60.69% | -38.53% | -11.56% | vs PTN |
| 6LPCN | $17.19M | $2.08 | +0.72% | -38.07% | -34.76% | -29.99% | vs PTN |
forward FY estimate
N/A
$300500.00
vs Estimate
$1.50M
Consensus Rating
Based on 3 analysts
Average Price Target
$53.50
+467.9% upside
Low
$47.50
Current
$9.42
High
$60.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.53 | $-0.42 | $-0.31 | 2 |
| Quarter ending Dec 2026 | $-0.99 | $-0.79 | $-0.58 | 2 |
| Quarter ending Mar 2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Quarter ending Jun 2027 | $-0.71 | $-0.71 | $-0.71 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-2.90 | $-2.18 | $-1.47 | 1 |
| FY 2028 | $-2.82 | $-2.13 | $-1.43 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.02M | $2.51M | $3.00M | 2 |
| Quarter ending Dec 2026 | $976000.00 | $976000.00 | $976000.00 | 1 |
| Quarter ending Mar 2027 | $4.65M | $4.65M | $4.65M | 1 |
| Quarter ending Jun 2027 | $200000.00 | $200000.00 | $200000.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $7.05M | $8.62M | $11.75M | 2 |
| FY 2028 | $6.00M | $7.33M | $10.00M | 3 |
